190 related articles for article (PubMed ID: 32492505)
1. Enhanced absorption, and efficacy of oral self-assembled paclitaxel nanocochleates in multi-drug resistant colon cancer.
Shanmugam T; Joshi N; Ahamad N; Deshmukh A; Banerjee R
Int J Pharm; 2020 Aug; 586():119482. PubMed ID: 32492505
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis.
Hu Y; Zhang K; Zhu X; Zheng X; Wang C; Niu X; Jiang T; Ji X; Zhao W; Pang L; Qi Y; Li F; Li L; Xu Z; Gu W; Zou H
Int J Nanomedicine; 2021; 16():2173-2186. PubMed ID: 33758505
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer.
Bai F; Wang C; Lu Q; Zhao M; Ban FQ; Yu DH; Guan YY; Luan X; Liu YR; Chen HZ; Fang C
Biomaterials; 2013 Aug; 34(26):6163-74. PubMed ID: 23706689
[TBL] [Abstract][Full Text] [Related]
4. Aerosol Delivery of Paclitaxel-Containing Self-Assembled Nanocochleates for Treating Pulmonary Metastasis: An Approach Supporting Pulmonary Mechanics.
Shanmugam T; Joshi N; Kaviratna A; Ahamad N; Bhatia E; Banerjee R
ACS Biomater Sci Eng; 2021 Jan; 7(1):144-156. PubMed ID: 33346632
[TBL] [Abstract][Full Text] [Related]
5. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
6. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
[TBL] [Abstract][Full Text] [Related]
7. Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in non-small-cell lung cancer after oral administration.
Lv PP; Wei W; Yue H; Yang TY; Wang LY; Ma GH
Biomacromolecules; 2011 Dec; 12(12):4230-9. PubMed ID: 22044456
[TBL] [Abstract][Full Text] [Related]
8. Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel.
Wang X; Chen Y; Dahmani FZ; Yin L; Zhou J; Yao J
Biomaterials; 2014 Aug; 35(26):7654-65. PubMed ID: 24927684
[TBL] [Abstract][Full Text] [Related]
9. PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery.
Chu B; Qu Y; Huang Y; Zhang L; Chen X; Long C; He Y; Ou C; Qian Z
Int J Pharm; 2016 Mar; 500(1-2):345-59. PubMed ID: 26794876
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
[TBL] [Abstract][Full Text] [Related]
11. Novel oral administrated paclitaxel micelles with enhanced bioavailability and antitumor efficacy for resistant breast cancer.
Zhang T; Luo J; Fu Y; Li H; Ding R; Gong T; Zhang Z
Colloids Surf B Biointerfaces; 2017 Feb; 150():89-97. PubMed ID: 27898360
[TBL] [Abstract][Full Text] [Related]
12. A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer.
Bu H; He X; Zhang Z; Yin Q; Yu H; Li Y
Int J Pharm; 2014 Aug; 471(1-2):206-13. PubMed ID: 24866272
[TBL] [Abstract][Full Text] [Related]
13. Trimethyl chitosan based conjugates for oral and intravenous delivery of paclitaxel.
He R; Yin C
Acta Biomater; 2017 Apr; 53():355-366. PubMed ID: 28189812
[TBL] [Abstract][Full Text] [Related]
14. A reconstituted thermosensitive hydrogel system based on paclitaxel-loaded amphiphilic copolymer nanoparticles and antitumor efficacy.
Liang Y; Dong C; Zhang J; Deng L; Dong A
Drug Dev Ind Pharm; 2017 Jun; 43(6):972-979. PubMed ID: 28121206
[TBL] [Abstract][Full Text] [Related]
15. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 3 agonist poly I:C reinforces the potency of cytotoxic chemotherapy via the TLR3-UNC93B1-IFN-β signaling axis in paclitaxel-resistant colon cancer.
Zhao J; Xue Y; Pan Y; Yao A; Wang G; Li D; Wang T; Zhao S; Hou Y
J Cell Physiol; 2019 May; 234(5):7051-7061. PubMed ID: 30387134
[TBL] [Abstract][Full Text] [Related]
17. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
Hu H; Lin Z; He B; Dai W; Wang X; Wang J; Zhang X; Zhang H; Zhang Q
J Control Release; 2015 Dec; 220(Pt A):189-200. PubMed ID: 26474677
[TBL] [Abstract][Full Text] [Related]
18. [Preparation, characterization of paclitaxel-loaded Pluronic P105 polymeric micelles and in vitro reversal of multidrug resistant tumor].
Wang YZ; Fang XL; Li YJ; Zhang ZW; Han LM; Sha XY
Yao Xue Xue Bao; 2008 Jun; 43(6):640-6. PubMed ID: 18822969
[TBL] [Abstract][Full Text] [Related]
19. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
Vredenburg MR; Ojima I; Veith J; Pera P; Kee K; Cabral F; Sharma A; Kanter P; Greco WR; Bernacki RJ
J Natl Cancer Inst; 2001 Aug; 93(16):1234-45. PubMed ID: 11504769
[TBL] [Abstract][Full Text] [Related]
20. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study.
Zabaleta V; Ponchel G; Salman H; Agüeros M; Vauthier C; Irache JM
Eur J Pharm Biopharm; 2012 Aug; 81(3):514-23. PubMed ID: 22516136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
